PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76), BIOD: 1.36 (-0.04)
Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)
ImmunoGen/Roche's Kadcyla Fails in Study, Shares Plunge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:44PM CST
ImmunoGen (IMGN) and partner Roche's Kadcyla failed to meet the primary endpoint in a phase III study conducted in HER2-positive metastatic breast cancer patients.
LCI: 42.29 (+1.79), IMGN: 5.90 (+0.13), BIOD: 1.36 (-0.04)
PharmAthene, Inc. (PIP) in Focus: Stock Adds 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 8:32AM CST
PharmAthene, Inc. (PIP) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
IP: 54.16 (-0.38), BIOD: 1.36 (-0.04)
Dermira (DERM) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 7:59AM CST
Dermira has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past 24 hours
DERM: 19.65 (+0.38), BIOD: 1.36 (-0.04)
Biodel fiscal Q4 results
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 5:41AM CST
BIOD: 1.36 (-0.04)
Biodel's (BIOD) CEO Errol De Souza on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Dec 17, 8:33PM CST
BIOD: 1.36 (-0.04)
Biodel beats by $0.15
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:09PM CST
BIOD: 1.36 (-0.04)
Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results
Marketwired - Wed Dec 17, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2014.
BIOD: 1.36 (-0.04)
Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 1:12PM CST
Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan 550 by May 27, 2015.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), SLXP: 114.92 (-1.18), BIOD: 1.36 (-0.04)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BGFV: 14.46 (-0.12), AXGN: 3.85 (+0.17), BRK.B: 151.54 (-0.21), Y: 466.26 (-0.32), BIOD: 1.36 (-0.04)
Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 210.12 (+0.95), ABBV: 66.21 (+1.86), BIOD: 1.36 (-0.04)
Biodel reports December 17
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:20PM CST
BIOD: 1.36 (-0.04)
Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014
Marketwired - Wed Dec 10, 3:00PM CST
Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
BIOD: 1.36 (-0.04)
Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 3:30PM CST
Merck (MRK) is set to acquire Cubist in an all-cash transaction valued at about $9.5 billion or $102 per share which will strengthen its hospital acute care portfolio.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04), HSP: 62.60 (-0.07)
Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 42.29 (+1.79), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)
Tetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:30AM CST
Tetraphase Pharmaceuticals, Inc. (TTPH) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
LCI: 42.29 (+1.79), TTPH: 38.86 (+0.53), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)
Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
Marketwired - Thu Dec 04, 3:19PM CST
Biodel Inc. (NASDAQ: BIOD) today announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia. The combination of the formulation and the auto-reconstitution device constitutes the Glucagon Emergency Management (GEM) system, which is intended to be a more user-friendly glucagon presentation compared to emergency kits currently marketed by Eli Lilly and Novo Nordisk. The Phase 1 proof of concept study is a 6-arm cross over trial in 12 healthy volunteers in which the pharmacokinetics, pharmacodynamics, and safety of 1 mg doses of the GEM glucagon formulation, administered subcutaneously and intramuscularly, will be compared to similar injections of both marketed glucagon products.
NVO: 43.80 (+1.08), BIOD: 1.36 (-0.04)
Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent Office Opposition Proceedings
Marketwired - Tue Nov 18, 11:26PM CST
Biodel Inc. (NASDAQ: BIOD) announced that it has successfully defended oppositions to two of its granted European patents for its ultra-rapid-acting insulin formulations, EP 2 319 500 and EP 2 106 790. A third party opposed Biodel's patents in July 2013, but the Opposition Division at the European Patent Office (EPO) recently ruled in favor of the validity of Biodel's patents. The EPO tribunal ruled that all claims of both patents are novel and inventive. Biodel therefore retains all of its patent claims as originally granted.
BIOD: 1.36 (-0.04)